SNDX · Syndax Pharmaceuticals, Inc.

Current Thesis

Syndax Pharmaceuticals' recovery case rests on Revuforj growth and expansion into earlier-line leukemia treatment; a weekly reclaim of $20 before a weekly close below $18.18 would establish the initial price recovery. This is a low-conviction inference, anchored to the September 11 reference close rather than an established support shelf.

The commercial-momentum narrative is dead — the previously identified $20 shelf had failed by the August 21 weekly close of $19.65, and the September 11 close was $18.18. That classification describes the market structure, not the failure of the medicines.

The clinical calendar also requires correction. Syndax's August 4 update describes EVOLVE-2 as ongoing; it does not promise second-half 2026 topline results. The second-half guidance covers other revumenib datasets, including BEAT AML and SAVE frontline results. A near-term EVOLVE-2 outcome therefore cannot underpin the recovery forecast. Syndax, August 4 business update.

Bullish and bearish views on Syndax Pharmaceuticals, Inc.

The model's bull view on Syndax Pharmaceuticals, Inc. (SNDX), in brief: Commercial growth remains measurable. Revuforj revenue reached $54.7 million in Q2 2026, up 91% annually and 12% sequentially, according to the August 4 release. These measurements support continued adoption despite the weaker share price. Company results. the August 4 release… The bear view: Analyst expectations have moved lower. JPMorgan reduced its target from $44 to $40 on August 11, 2026; UBS reduced its target from $37 to $33 on August 21. Both retained positive ratings. These are observable revisions, not evidence that investor demand has strengthened. Dated… Both cases follow in full.

Bull Case

• Commercial growth remains measurable. Revuforj revenue reached $54.7 million in Q2 2026, up 91% annually and 12% sequentially, according to the August 4 release. These measurements support continued adoption despite the weaker share price. Company results.
• the August 4 release distinguishes those measures. Company results.
• Management appearance is now confirmed. The September 1 announcement schedules a September 15 fireside chat, replacing the previously unconfirmed conference possibility with a company-dated appearance. It announces no clinical readout. Conference announcement.

Bear Case

• Analyst expectations have moved lower. JPMorgan reduced its target from $44 to $40 on August 11, 2026; UBS reduced its target from $37 to $33 on August 21. Both retained positive ratings. These are observable revisions, not evidence that investor demand has strengthened. Dated analyst actions.
• Development spending continues to rise. Q2 2026 research and development expense was $68.0 million against $62.2 million a year earlier, according to the August 4 release. Company results.
• The former shelf remains lost. The September 11, 2026 adjusted close of $18.18 remains below the previously published $20 threshold. A conference appearance does not itself repair that measured price failure.

Setup & Price Structure

The September 11, 2026 adjusted daily close was $18.18, with the shares 27.7% below the supplied 52-week high of $25.15 and down 0.4% over three months. The 14-day relative strength index was 36.9. These measurements describe weak momentum; they do not establish a reversal.

The $20 former shelf defines the recovery test. The $18.18 September 11 close defines its prospective invalidation threshold; it is not presented as independently verified historical support. A weekly close above $20 before the downside condition occurs would satisfy this limited recovery case, without establishing clinical success.

Positioning remains unmeasured. The August analyst reductions document changes in published expectations, while the September 15 appearance creates a dated attention event. Neither supplies evidence of crowded ownership, retail participation or a rising moving average.

Catalyst Calendar (next 30 days)

No additional company-confirmed event date inside this window was established. The August 4 update places axatilimab Phase 2 results in the fourth quarter of 2026 without a specific day. Business update.

Elapsed catalysts

• 2026-09-15 — H.C. Wainwright conference. Syndax schedules its fireside chat for 10:00 a.m. Eastern, according to the September 1 announcement. The appearance provides an opportunity for commercial and development commentary; the announcement does not schedule new results. Company announcement. (passed 5d ago)

What Would Change Our Mind

Loss of the September 11 reference close would end the provisional recovery case: a weekly close below $18.18 is the observable break. The earlier $20 thesis threshold has already failed; the present condition does not reverse that historical outcome.

Conversely, a weekly reclaim of $20 before invalidation would resolve the defined price-recovery forecast; broader clinical claims would still require trial results.

Correlation Notes

Syndax remains a single-name clinical and commercial case. No paired return series supports a claim about its correlation with biotechnology shares or an oncology theme.

Incyte provides a specific operating connection: Syndax's August 4 release states that collaboration revenue represents 50% of Niktimvo's net commercial profit. That contractual link does not establish share-price correlation. Company results.